Watch AURX. Know when insiders buy.
One email the day a filing lands. Free.
AURX
Nuo Therapeutics, Inc.
1.21
+0.10 +9.01%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $58.6MP/E —DIV YIELD —FCF YIELD -4.18%REV TTM —NET INCOME −$2MNET CASH $449K52W 0.77 – 3.23SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$167K | −$278K | — | -0.01 | −$236K | $253K | −$490K | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$446K | −$618K | — | -0.01 | −$784K | $847 | −$785K | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$579K | −$578K | — | -0.01 | −$423K | $43K | −$466K | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$540K | −$538K | — | -0.01 | −$707K | $0 | −$707K | Oct 30 |
| Q2 2025 · Jun 30 | — | — | — | −$652K | −$650K | — | -0.01 | $262K | $2K | $261K | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$745K | −$746K | — | -0.02 | $2K | $230K | −$228K | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$629K | −$497K | — | -0.01 | −$491K | $0 | −$491K | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$577K | −$578K | — | -0.01 | −$487K | $151K | −$638K | Oct 30 |
| Q2 2024 · Jun 30 | — | — | — | −$542K | −$540K | — | -0.01 | −$691K | $4K | −$695K | Oct 30 |
| Q1 2024 · Mar 31 | — | — | — | −$709K | −$709K | — | -0.02 | −$562K | $0 | −$562K | Oct 30 |
| Q4 2023 · Dec 31derived | — | — | — | −$652K | −$653K | — | -0.02 | −$671K | $0 | −$671K | Apr 1 |
| Q3 2023 · Sep 30 | — | — | — | −$790K | −$791K | — | -0.02 | −$795K | $2K | −$797K | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$2.5M | −$2.5M | — | -0.05 | −$865K | $275K | −$1.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$2.5M | −$2.3M | — | -0.05 | −$2.2M | $155K | −$2.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$3.2M | −$3.2M | — | -0.08 | −$3.2M | $7K | −$3.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$3.3M | −$3.2M | — | -0.08 | −$3.7M | $60K | −$3.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$91K | −$91K | — | -0.03 | −$120K | $0 | −$120K | — | — |
| FY2020 · to Dec 31 | — | — | −$378K | −$91K | — | 0.27 | −$54K | $0 | −$54K | — | — |
Every number comes from Nuo Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.